MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Every figure this model derived for MDGL, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 8,569,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 838,753,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 1,199,180,000 AssetsCurrent 2026-06-30
current liabilities 374,204,000 LiabilitiesCurrent 2026-06-30
equity 523,724,000 StockholdersEquity 2026-06-30
interest expense 31,507,000 InterestExpenseNonoperating 2026-06-30
ocf -197,716,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 1,283,940,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 121,429,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up MDGL on one particular measure came for.

RatioValue
cash operating margin-15.55
current ratio3.2
current ratio reported3.2
dilution pct5.46
fcf margin-16.07
interest cover-10.24
operating margin-25.13
owner earnings margin-25.52
revenue growth149.04
revenue growth per share136.14
roic-989.19
rule of 40123.92
sbc pct revenue9.46

What to be careful about

What this model itself distrusts about MDGL's figures. Written by the derivation as it ran, not added afterwards.